Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
Cormedix Inc (CRMD) is a clinical-stage biopharmaceutical company pioneering novel therapies for life-threatening infectious and inflammatory conditions. This news hub provides investors and healthcare stakeholders with essential updates on DefenCath developments, regulatory milestones, and therapeutic pipeline progress.
Access timely announcements including FDA correspondence, clinical trial data, and commercialization strategies for CRMD's catheter lock solutions. Our curated collection features earnings reports, partnership disclosures, and scientific presentations relevant to infection prevention in critical care settings.
Key updates cover therapeutic candidate advancements, intellectual property developments, and market expansion initiatives. Monitor progress in addressing bloodstream infections through CRMD's specialized antimicrobial formulations designed for high-risk patient populations.
Bookmark this page for structured access to verified corporate communications and analysis of how CRMD navigates the complex biopharmaceutical regulatory landscape. Stay informed on developments impacting both patient care standards and long-term therapeutic innovation.
CorMedix presented new hospital admission and health economic data at ASN Kidney Week 2024, analyzing bloodstream infections (BSIs) in hemodialysis patients using central venous catheters. The study of 91,448 patients revealed that 25% were admitted with BSIs. Key findings showed median hospital stays of 16 days, with 53.8% requiring ICU care. The median total cost per admission was $157,000, with $65,000 for ICU care. The study reported 10.3% in-hospital mortality and 26.8% readmission rates within 90 days. Patient demographics showed 58.2% white, 27.1% black, with 47% from disadvantaged neighborhoods.
CorMedix Inc. (Nasdaq: CRMD) has announced a new commercial supply contract with a top-five mid-sized dialysis operator for DefenCath® (taurolidine and heparin) in the US. This agreement will provide DefenCath access to adult kidney failure patients receiving hemodialysis through a central venous catheter at over 200 outpatient dialysis clinics nationwide.
CorMedix received NDA approval for DefenCath on November 15, 2023, and began commercialization in the inpatient setting on April 15, 2024. Outpatient reimbursement from CMS took effect on July 1st, with shipments to outpatient facilities commencing in July. The company anticipates shipments under this new agreement to begin in Q4.
CEO Joseph Todisco stated that this agreement, combined with existing customer agreements, allows CorMedix to make DefenCath available to patients at approximately 60% of US outpatient dialysis centers.
CorMedix Inc. (Nasdaq: CRMD) has announced a new commercial supply contract with a top-tier mid-sized dialysis operator in the US for DefenCath® (taurolidine and heparin). This agreement will provide DefenCath access to adult kidney failure patients receiving hemodialysis through central venous catheters at over 250 outpatient dialysis clinics across the country.
CorMedix received NDA approval for DefenCath on November 15, 2023, and began commercialization in the inpatient setting on April 15, 2024. Outpatient reimbursement from CMS took effect on July 1st, with shipments to outpatient facilities commencing in July. The company anticipates shipments under this new agreement to begin in early Q4 2024.
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference in New York, NY from September 17-19, 2024. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 10:55 AM EDT, along with one-on-one investor meetings.
The event provides an opportunity for CorMedix to showcase its focus on developing and commercializing therapeutic products for preventing and treating life-threatening conditions and diseases. Investors and interested parties can access a live webcast of the fireside chat through a provided link, with a replay available later on the company's website under the 'Events and Presentations' section.
CorMedix Inc. (Nasdaq: CRMD) has announced a multi-year commercial supply contract with a major global healthcare company for DefenCath® (taurolidine and heparin). The agreement targets up to 4,000 patients in over 2,000 US clinics. DefenCath, approved by the FDA on November 15, 2023, began commercialization in inpatient settings on April 15, 2024. Outpatient reimbursement from CMS took effect on July 1st, with shipments commencing in July. CorMedix expects shipments under this new agreement to start in Q4 2024. CEO Joseph Todisco expressed excitement about providing access to DefenCath for thousands of adult patients at risk for catheter-related bloodstream infections, building on recent progress with smaller customers.
CorMedix Inc. (NASDAQ: CRMD) reported Q2 and H1 2024 financial results and provided a business update. Key highlights include:
- Initial net sales of $0.8 million for Q2 2024, primarily from inpatient trade stocking
- Unaudited Q3 quarter-to-date net sales of $5.2 million as of August 13th, driven by outpatient setting orders
- Cash and short-term investments of $45.6 million as of June 30, 2024
- Net loss of $14.2 million ($0.25 per share) for Q2 2024, compared to $11.3 million ($0.25 per share) in Q2 2023
- Operating expenses increased 32% to $15.6 million in Q2 2024
- Company believes it has sufficient resources to fund operations for at least 12 months
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its plan to release second quarter 2024 financial results on August 14, 2024, before the market opens. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day.
Investors and interested parties can access the conference call through the following options:
- Domestic: 1-877-270-2148
- International: 1-412-902-6510
- Webcast: Available via provided link
This announcement indicates CorMedix's commitment to transparency and shareholder communication, providing an opportunity for stakeholders to gain insights into the company's financial performance and recent developments.
CorMedix Inc. (Nasdaq: CRMD) has announced the commercialization of DefenCath® (taurolidine and heparin) for outpatient dialysis centers and vascular access clinics. This launch, effective from July 1st, aligns with the Centers for Medicare & Medicaid Services (CMS) reimbursement for outpatient use.
DefenCath, approved by the FDA under the Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, initially launched for inpatient settings on April 15, 2024. The product is designed to reduce catheter-related bloodstream infections (CRBSI) in adults undergoing chronic hemodialysis through a central venous catheter.
CorMedix has begun shipping orders to dialysis operators, with additional customer agreements expected soon. The CEO, Joseph Todisco, expressed optimism about expanding access and the effective rollout by customers.
CorMedix (NASDAQ: CRMD) has received supportive feedback from the FDA regarding its plans to expand the use of DefenCath to adult Total Parenteral Nutrition (TPN) patients. The company plans to submit a complete clinical protocol by the third quarter of 2024 and aims to start the program by year-end. The FDA also requires a pediatric study under the Pediatric Research Equity Act. An independent market assessment shows a critical unmet need for DefenCath in TPN patients, with an estimated CLABSI rate over 25% and an addressable market of 5 million yearly infusions. Further details will be shared in CorMedix's Q2 earnings call in August.
CorMedix announced that CMS has granted pass-through status to DefenCath under the Out-Patient Prospective Payment System (OPPS). This status allows for separate Medicare Part B payments for DefenCath for at least two years, and up to three years, in outpatient settings. DefenCath, a combination of taurolidine and heparin, is used to reduce catheter-related bloodstream infections (CRBSI) in chronic hemodialysis patients using central venous catheters. The company estimates around 100,000 HD-CVC placements annually, highlighting the importance of reimbursement for DefenCath to prevent CRBSIs. However, DefenCath is contraindicated in patients with heparin-induced thrombocytopenia or hypersensitivity to any of its components.
